Member Info for ForFXSake

..I note.

Volume back to under 1m. Price back towards 2p. Like Friday and Monday never happened.

It all now depends on a number of key things such as how much value does Oxilio put on the findings of their research and how adept Anne is in gauging Oxilio's expectations and negotiating the best deal she can for us without blowing it out.

If Oxilio's research yielded better than expected results then they may be willing to pay more to hang on to it. We know that they have said that they intend to target multiple cancers, so that might be promising if Anne knew they were only originally targeting a specific type of cancer.

We're just guessing as everything is undisclosed at the moment. If it remains that way then my assumption would be that she is happy to treat it in the same way as Blackwell..as an opportunity for some quick cash during a time of need .

When Blackwell announced Oxilio's interest, I got the impression that he didn't really take it seriously. He was just glad to take a bit of cash upfront and announce some good news in what was a dark time. He had nothing really to lose as he wasn't relinquishing any rights for us to develop/license NXP001 for its original CINV target market.

I therefore reckon he was happy to take a low amount at the time and keep it undisclosed. We didn't see any huge figures in the results and we still had a cash call.

An early win would be nice Soup but I got the distinct impression from the RNS that NXP004 was going to have undergo further research in order to be of any value, similar to NXP002:

"The net proceeds of the Placing are expected to be used by the Company to:
o perform further preclinical studies to determine the feasibility of NXP002 as an inhaled formulation and generate a more robust data package for lead asset NXP002;

o pursue additional business development opportunities for NXP001 in oncology should Oxilio not exercise the option to license NXP001 in oncology;

o perform further research on NXP004 to supplement existing data; and

o provide additional working capital."

Might be our last chance at a small boost to get us off these miserable lows before slip into hibernation mode while we wait for the testing period to complete

A mention on the website wouldn't go amiss. That shouldn't be too difficult or costly to implement.

Thanks Soup, at least there is that then.

I haven't regained confidence yet.

Everything we thought had been achieved be the old board has either been written off or kicked into the long grass pending further lengthy testing.

The only deal that appears to have been delivered is completely intangible when it comes to valuation. I'd hoped we'd at least get some disclosure on the upfronts.

Innovate grant looks increasingly unlikely in Q1. Very few days left.

Recent trading before RNS's suggests things are still leaky. Lack of TR1's following big volume also seems odd to me.

Nothing has actually improved at this point other than that we have been told that it has.

Still a nervy waiting game

..I note.

Perhaps our sellers have had a change of heart.

Ramon = rampy....android predictive text...grrrr!

I tend to read all comments on this board, except perhaps during the high volume when I skip through some of the newcomer repetitive Ramon stuff., I don't remember seeing anything controversial from anyone here.

There 513.36m shares in issue pre placing. 3% is about 15.4m

Yep. There's nothing like having big sellers around to put off buyers. It's quite a powerful suppressor. Once the market knows that influence is no longer there we might see some interest return.

It will be interesting to note the trade dates on any future TR1's.

Around 13% of the issued share capital changed hands over the last two big volume days. I'm surprised we haven't seen at least 1 TR1 from that

Influencing clients through an analysis report is one thing, letting them know that news of a deal is about to drop is something else.

I'm not sure what drove Friday's activity. I'm not even sure that it originated from NFX sources. However, it does give off a whiff of orchestration when those types of timings occur.

I'll feel happier once the EGM is done and dusted.

Oxilio have exercised their right to develop NXP001 but we have no idea how much money has changed hands nor how much will at this point. In the meantime, this news was somehow known about on Friday and generated two days of massive volume...a great opportunity for old money to get out.

Here we are on day 3, back to almost normal volume and not a single TR1 to show for it all. Now the market does appear to be generally down today and things might just be having a breather but I can well understand how people are feeling cautious about all this, especially after all the BS of the past year.

Flashy! Is that where you place your orders?

Well if the market is huge, royalties are 25% and Anne has said it is not material, she obviously doesn't think it will get to market

As the patent is filed under Ebers Tech then I'm assuming they have the right to use it, if they so choose. I'm assuming NFX would get some kind of royalty for this but have no control or knowledge of how or when this would come about.

If Ebers are not forthcoming and/or have shown no interest in developing further cocrystals then it would be completely reasonable for the new board to not pin their hopes on this area and adjust their strategy accordingly.

So do these two patented cocrystals basically do the same thing in different ways? The Joanitis patent appears to have been submitted earlier so was it always the frontrunner and did Ebers always have the intention of selecting one over the other or have they just decided to shelve the product line that JH's cocrystal would have been the basis of?

If so, were members of the old board aware of the potential risk of NFX losing out to a competing cocrystal patent?